Despite recent declines, three healthcare stocks—Intuitive Surgical, HCA Healthcare, and Abbott Laboratories—are positioned as long-term buy-and-hold opportunities. While facing macroeconomic headwinds and near-term challenges, each company has strong underlying fundamentals, innovative products, and exposure to growing healthcare trends that could drive significant long-term returns.

Intuitive Surgical's stock has declined approximately 30% since the start of 2026, presenting a potential buying opportunity for growth investors. Despite the stock decline, the company's da Vinci surgical robot system continues to show strong fundamentals with 12% year-over-year growth in installed systems and 17% growth in procedures performed. The company generates 75% of revenue from recurring parts and services, creating an annuity-like revenue stream. Historically, the stock has recovered from similar 30%+ declines eight times since its IPO.

Intuitive Surgical stock has fallen 30% from early 2025 highs but Wall Street analysts maintain an average price target of $570, suggesting 30%+ upside potential. The surgical robotics leader's da Vinci system shows strong demand with 12% year-over-year growth in installed systems and 17% growth in surgeries performed. While the stock trades at a lofty 51x P/E ratio, analysts believe the company's recurring revenue from instruments, accessories, and services (75% of revenue) and long-term market opportunity justify recovery, supported by historical precedent of similar drawdowns followed by strong recoveries.

Medtronic is presented as an attractive investment opportunity for dividend, value, and growth investors. The stock has declined 40% from its 2021 peak, offering attractive valuations with a 3.7% dividend yield and 48 consecutive annual dividend increases. The company is ramping up its Hugo surgical robot to compete in the growing surgical robotics market, with potential for significant upside if the market recognizes its growth prospects.

The article recommends three healthcare stocks poised to benefit from rising federal healthcare spending projected to exceed $3 trillion within a decade. Pfizer offers an attractive 6.5% dividend yield with a robust drug pipeline; Intuitive Surgical dominates robotic surgery with recurring revenue from instruments and servicing; and Eli Lilly is capitalizing on blockbuster GLP-1 weight-loss drugs with strong revenue growth.

Intuitive Surgical's stock has fallen 20% in 2026, entering its own bear market. Despite the decline, two-thirds of analysts rate it a buy with a 33% upside price target. The company continues rapid growth with 12% year-over-year increases in da Vinci system installations. However, the stock remains richly valued at 52x P/E ratio and highly volatile, making it suitable only for aggressive growth investors with long-term commitment.

CNBC's Jim Cramer warns that while the current market is compared to the 1999 dot-com bubble, today's market is actually more brutal in punishing disappointing stocks. The market is heavily concentrated in AI and data center stocks while aggressively selling healthcare and medical technology companies that miss earnings expectations. Cramer defends AI investments as producing real business results, citing strong earnings from major tech companies.

Medtronic, a medical device company down 40% from its 2021 peak, is attracting investor interest due to its 3.6% dividend yield and upcoming business improvements. The company is spinning off its diabetes division, launching its Hugo surgical robot to compete with Intuitive Surgical's da Vinci, and pursuing strategic acquisitions. With 48 consecutive years of dividend increases and approaching Dividend King status, analysts suggest the stock could recover as business trends improve.

While Intuitive Surgical dominates surgical robotics with a powerful business model, its lofty 55x P/E ratio and recent 20% drawdown make it expensive. Medtronic, trading at 22x P/E with a 3.6% dividend yield and 48 consecutive annual dividend increases, presents a more attractive buy-and-hold opportunity as it launches its Hugo surgical robot with significant growth potential.

The global computer vision in healthcare market is projected to grow from $4.37 billion in 2026 to $33.4 billion by 2036, at a CAGR of 22.6%. Growth is driven by AI-integrated diagnostic systems, radiologist shortages, and precision medicine adoption. Software and medical imaging segments lead the market, while Asia-Pacific is expected to see the fastest regional growth.

Intuitive Surgical's stock has surged 580% over the past decade, significantly outperforming the S&P 500. While the company is known for its da Vinci surgical robots, the real growth driver is its recurring revenue from instruments, accessories, and services, which comprise 75% of revenues. With 11,395 robots installed globally and surgeries performed increasing 17% year-over-year, the company has built an annuity-like business model that generates consistent cash flow.

The article analyzes two underperforming healthcare stocks as potential buying opportunities: Intuitive Surgical and Vertex Pharmaceuticals. Despite recent headwinds including tariffs, increased competition, and portfolio diversification challenges, both companies have strong long-term prospects. Intuitive Surgical maintains leadership in robotic-assisted surgery with a vast addressable market, while Vertex Pharmaceuticals has a stable cystic fibrosis business and promising pipeline candidates. Both stocks are trading around $425-$460, allowing investors to purchase two shares with $1,000.